@article{b9f9a12772204bad957b0d7940c3278a,
title = "Aurone derivatives as Vps34 inhibitors that modulate autophagy",
abstract = "We report in this study the identification of a natural product-like antagonist (1a) of Vps34 as a potent autophagy modulator via structure-based virtual screening. Aurone derivative 1a strongly inhibited Vps34 activity in cell-free and cell-based assays. Significantly, 1a prevents autophagy in human cells induced either by starvation or by an mTOR inhibitor. In silico modeling and kinetic data revealed that 1a could function as an ATP-competitive inhibitor of Vps34. Moreover, it suppressed autophagy in vivo and without inducing heart or liver damage in mice. 1a could be utilized as a new motif for more selective and efficacious antagonists of Vps34 for the potential treatment of autophagy-related human diseases.",
keywords = "Aurone derivative, Autophagy, Heart or liver damage, Inhibitor, Natural products, Structure-based virtual screening, Vesicle trafficking, Vps34",
author = "Guodong Li and Boyle, {Joshua William} and Ko, {Chung Nga} and Wu Zeng and Wong, {Vincent Kam Wai} and Wan, {Jian Bo} and Chan, {Philip Wai Hong} and MA, {Edmond Dik Lung} and Leung, {Chung Hang}",
note = "Funding Information: This work is supported by Hong Kong Baptist University ( FRG2/16–17/007 , FRG2/17–18/003 , China), the Health and Medical Research Fund ( HMRF/14150561 , China), the Research Grants Council ( HKBU/12301115 , China), the National Natural Science Foundation of China ( 21575121 and 21775131 , China), the Hong Kong Baptist University Century Club Sponsorship Scheme 2018 (China), the Interdisciplinary Research Matching Scheme ( RC-IRMS/16–17/03 , China), Interdisciplinary Research Clusters Matching Scheme ( RC-IRCs/17–18/03 , China), Innovation and Technology Fund ( ITS/260/16FX , China), Matching Proof of Concept Fund ( MPCF-001–2017/18 , China), Collaborative Research Fund ( C5026-16G , China), SKLEBA and HKBU Strategic Development Fund ( SKLP_1718_P04 , China), the Science and Technology Development Fund, Macao SAR ( 0072/2018/A2 , China), the University of Macau ( MYRG2016-00151-ICMS-QRCM and MYRG2018-00187-ICMS , China), and a Discovery Project Grant ( DP160101682 , Australia) from the Australian Research Council . We would like to thank Dr. Chao YANG for his kind help during in the study. We also thank Dr. Jia-Hong LU (Institute of Chinese Medical Sciences, University of Macau, Taipa, Macau, China) for providing GFP-LC3 HeLa cells. Funding Information: This work is supported by Hong Kong Baptist University (FRG2/16?17/007, FRG2/17?18/003, China), the Health and Medical Research Fund (HMRF/14150561, China), the Research Grants Council (HKBU/12301115, China), the National Natural Science Foundation of China (21575121 and 21775131, China), the Hong Kong Baptist University Century Club Sponsorship Scheme 2018 (China), the Interdisciplinary Research Matching Scheme (RC-IRMS/16?17/03, China), Interdisciplinary Research Clusters Matching Scheme (RC-IRCs/17?18/03, China), Innovation and Technology Fund (ITS/260/16FX, China), Matching Proof of Concept Fund (MPCF-001?2017/18, China), Collaborative Research Fund (C5026-16G, China), SKLEBA and HKBU Strategic Development Fund (SKLP_1718_P04, China), the Science and Technology Development Fund, Macao SAR (0072/2018/A2, China), the University of Macau (MYRG2016-00151-ICMS-QRCM and MYRG2018-00187-ICMS, China), and a Discovery Project Grant (DP160101682, Australia) from the Australian Research Council. We would like to thank Dr. Chao YANG for his kind help during in the study. We also thank Dr. Jia-Hong LU (Institute of Chinese Medical Sciences, University of Macau, Taipa, Macau, China) for providing GFP-LC3 HeLa cells.",
year = "2019",
month = may,
doi = "10.1016/j.apsb.2019.01.016",
language = "English",
volume = "9",
pages = "537--544",
journal = "Acta Pharmaceutica Sinica B",
issn = "2211-3835",
publisher = "Elsevier BV",
number = "3",
}
